Graikija - graikų - Εθνικός Οργανισμός Φαρμάκων

ΣΕΡΒΙΕ ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ Ε.Π.Ε. - gliclazide - ΔΙΣΚΙΟ ΒΡΑΔΕΙΑΣ ΑΠΟΔΕΣΜΕΥΣΗΣ - 80mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Europos Sąjunga - graikų - EMA (European Medicines Agency)

leo pharma a/s - tacrolimus - Δερματίτιδα, Ατοπική - Άλλα δερματολογικά παρασκευάσματα - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. συμβαίνουν τέσσερις ή περισσότερες φορές ανά έτος) που είχαν μια πρώτη απάντηση σε ένα μέγιστο έξι εβδομάδες θεραπεία δύο φορές την ημέρα αλοιφή τακρόλιμους (βλάβες εκκαθαριστεί, σχεδόν καθαρίσει ή ελαφρώς επηρεάζονται).

Europos Sąjunga - graikų - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - Εμβόλια - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. Η χρήση αυτού του εμβολίου θα πρέπει να γίνεται σύμφωνα με τις επίσημες συστάσεις.

Graikija - graikų - Εθνικός Οργανισμός Φαρμάκων

baxter hellas ΕΠΕ Μαρίνου Αντύπα 47 & Ανάφης, 141 21 Ν. Ηράκλειο 210.2880000 - sodium chloride; potassium chloride; magnesium chloride hexahydrate; sodium acetate trihydrate; sodium gluconate - sol.inf (ΔΙΑΛΥΜΑ ΓΙΑ ΕΓΧΥΣΗ) - (5.26+0.37+0.30 +3.68+5.20)g/l - sodium chloride 5,26g; potassium chloride 0,37g; magnesium chloride hexahydrate 0,3g; sodium acetate trihydrate 3,68g; sodium gluconate 5,2g - electrolytes

Kipras - graikų - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

baxter (hellas) epe (0000008332) 47, marinou antypa & anafis str, n. herakleio-attiki, 141 21 - sodium chloride; potassium chloride; sodium acetate trihydrate; magnesium chloride hexahydrate; sodium gluconate - solution for infusion - sodium chloride (0007647145) 5,26g; potassium chloride (0007447407) 0,37g; sodium acetate trihydrate (0006131904) 3,68g; magnesium chloride hexahydrate (0007791186) 0,3g; sodium gluconate (0000527071) 5,2g - electrolytes

Graikija - graikų - Εθνικός Οργανισμός Φαρμάκων

ph & t spa, italy - latanoprost - ΟΦΘΑΛΜΙΚΕΣ ΣΤΑΓΟΝΕΣ, ΔΙΑΛΥΜΑ - 0,005% - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Graikija - graikų - Εθνικός Οργανισμός Φαρμάκων

dr. falk pharma gmbh, germany - macrogol, combinations - ΚΟΝΙΣ ΓΙΑ ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ - pd.or.sol. - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Graikija - graikų - Εθνικός Οργανισμός Φαρμάκων

meda pharmaceuticals s.a., greece - macrogol, combinations - ΚΟΝΙΣ ΓΙΑ ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ - (13,125+0,3507+0,1785+0,0466) g/s - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Graikija - graikų - Εθνικός Οργανισμός Φαρμάκων

ΙΦΕΤ ΑΕ - Χλωριούχο mivacurium - ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ - 2mg/ml - ineof00503 - mivacurium chloride - 0.000000

Graikija - graikų - Εθνικός Οργανισμός Φαρμάκων

farmanic abee - potassium chloride - ΣΙΡΟΠΙ - 500mg/5ml - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ